123 related articles for article (PubMed ID: 38108262)
1. Novel signatures of prostate cancer progression and therapeutic resistance.
Wang J; Ben-David R; Mehrazin R; Yang W; Tewari AK; Kyprianou N
Expert Opin Ther Targets; 2023; 27(12):1195-1206. PubMed ID: 38108262
[TBL] [Abstract][Full Text] [Related]
2. Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
Cheng Q; Butler W; Zhou Y; Zhang H; Tang L; Perkinson K; Chen X; Jiang XS; McCall SJ; Inman BA; Huang J
Eur Urol; 2022 May; 81(5):446-455. PubMed ID: 35058087
[TBL] [Abstract][Full Text] [Related]
3. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
[TBL] [Abstract][Full Text] [Related]
4. Multifocal Signal Modulation Therapy by Celecoxib: A Strategy for Managing Castration-Resistant Prostate Cancer.
Benelli R; Barboro P; Costa D; Astigiano S; Barbieri O; Capaia M; Poggi A; Ferrari N
Int J Mol Sci; 2019 Dec; 20(23):. PubMed ID: 31816863
[TBL] [Abstract][Full Text] [Related]
5. Anti-androgen therapy induces transcriptomic reprogramming in metastatic castration-resistant prostate cancer in a murine model.
Zhao Y; Peng X; Baldwin H; Zhang C; Liu Z; Lu X
Biochim Biophys Acta Mol Basis Dis; 2021 Jul; 1867(7):166151. PubMed ID: 33892077
[TBL] [Abstract][Full Text] [Related]
6. SPP1 Promotes Enzalutamide Resistance and Epithelial-Mesenchymal-Transition Activation in Castration-Resistant Prostate Cancer via PI3K/AKT and ERK1/2 Pathways.
Pang X; Zhang J; He X; Gu Y; Qian BZ; Xie R; Yu W; Zhang X; Li T; Shi X; Zhou Y; Cui Y
Oxid Med Cell Longev; 2021; 2021():5806602. PubMed ID: 34721759
[TBL] [Abstract][Full Text] [Related]
7. Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer.
Ferrari N; Granata I; Capaia M; Piccirillo M; Guarracino MR; Venè R; Brizzolara A; Petretto A; Inglese E; Morini M; Astigiano S; Amaro AA; Boccardo F; Balbi C; Barboro P
Cell Commun Signal; 2017 Dec; 15(1):51. PubMed ID: 29216878
[TBL] [Abstract][Full Text] [Related]
8. p66Shc protein through a redox mechanism enhances the progression of prostate cancer cells towards castration-resistance.
Miller DR; Ingersoll MA; Chatterjee A; Baker B; Shrishrimal S; Kosmacek EA; Zhu Y; Cheng PW; Oberley-Deegan RE; Lin MF
Free Radic Biol Med; 2019 Aug; 139():24-34. PubMed ID: 31100478
[TBL] [Abstract][Full Text] [Related]
9. Alterations of plasma exosomal proteins and motabolies are associated with the progression of castration-resistant prostate cancer.
Liu P; Wang W; Wang F; Fan J; Guo J; Wu T; Lu D; Zhou Q; Liu Z; Wang Y; Shang Z; Chan FL; Yang W; Li X; Zhao SC; Zheng Q; Wang F; Wu D
J Transl Med; 2023 Jan; 21(1):40. PubMed ID: 36681849
[TBL] [Abstract][Full Text] [Related]
10. Profiling Prostate Cancer Therapeutic Resistance.
Wade CA; Kyprianou N
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562686
[TBL] [Abstract][Full Text] [Related]
11. Role of extracellular vesicles in castration-resistant prostate cancer.
Liao C; Huang Z; Liu J; Deng M; Wang L; Chen Y; Li J; Zhao J; Luo X; Zhu J; Wu Q; Fu W; Sun B; Zheng J
Crit Rev Oncol Hematol; 2024 May; 197():104348. PubMed ID: 38588967
[TBL] [Abstract][Full Text] [Related]
12. B7-H3 as a Therapeutic Target in Advanced Prostate Cancer.
Guo C; Figueiredo I; Gurel B; Neeb A; Seed G; Crespo M; Carreira S; Rekowski J; Buroni L; Welti J; Bogdan D; Gallagher L; Sharp A; Fenor de la Maza MD; Rescigno P; Westaby D; Chandran K; Riisnaes R; Ferreira A; Miranda S; Calì B; Alimonti A; Bressan S; Nguyen AHT; Shen MM; Hawley JE; Obradovic A; Drake CG; Bertan C; Baker C; Tunariu N; Yuan W; de Bono JS
Eur Urol; 2023 Mar; 83(3):224-238. PubMed ID: 36114082
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic Plasticity - Alternate Transcriptional Programs Driving Treatment Resistant Prostate Cancer.
Nanda JS; Koganti P; Perri G; Ellis L
Crit Rev Oncog; 2022; 27(1):45-60. PubMed ID: 35993978
[TBL] [Abstract][Full Text] [Related]
14. Castration-resistant prostate cancer without metastasis at presentation may achieve cancer-specific survival in patients who underwent prior radical prostatectomy.
Kodama H; Koie T; Oikawa M; Narita T; Tanaka T; Noro D; Iwamura H; Tobisawa Y; Yoneyama T; Hashimoto Y; Ohyama C
Int Urol Nephrol; 2020 Apr; 52(4):671-679. PubMed ID: 31897875
[TBL] [Abstract][Full Text] [Related]
15. Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.
Abudurexiti M; Zhu W; Wang Y; Wang J; Xu W; Huang Y; Zhu Y; Shi G; Zhang H; Zhu Y; Shen Y; Dai B; Wan F; Lin G; Ye D
Prostate; 2020 Sep; 80(12):950-961. PubMed ID: 32648618
[TBL] [Abstract][Full Text] [Related]
16. HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a γ-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutamide in vitro.
Du Z; Li L; Sun W; Wang X; Zhang Y; Chen Z; Yuan M; Quan Z; Liu N; Hao Y; Li T; Wang J; Luo C; Wu X
Int J Oncol; 2018 Jul; 53(1):99-112. PubMed ID: 29658567
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer.
Chen X; Liu J; Cheng L; Li C; Zhang Z; Bai Y; Wang R; Han T; Huang C; Kong Y; Feng F; Liu X
Prostate; 2020 Feb; 80(3):256-266. PubMed ID: 31856338
[TBL] [Abstract][Full Text] [Related]
18. MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer.
Li Q; Wang M; Hu Y; Zhao E; Li J; Ren L; Wang M; Xu Y; Liang Q; Zhang D; Lai Y; Liu S; Peng X; Zhu C; Ye L
Theranostics; 2021; 11(12):5794-5812. PubMed ID: 33897882
[No Abstract] [Full Text] [Related]
19. lncRNA HOXD-AS1 Regulates Proliferation and Chemo-Resistance of Castration-Resistant Prostate Cancer via Recruiting WDR5.
Gu P; Chen X; Xie R; Han J; Xie W; Wang B; Dong W; Chen C; Yang M; Jiang J; Chen Z; Huang J; Lin T
Mol Ther; 2017 Aug; 25(8):1959-1973. PubMed ID: 28487115
[TBL] [Abstract][Full Text] [Related]
20. Non-Coding RNAs Set a New Phenotypic Frontier in Prostate Cancer Metastasis and Resistance.
Altschuler J; Stockert JA; Kyprianou N
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]